Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia
Trial ID or NCT#
NCT01460160
Status
NOT RECRUITING
Purpose
The purpose of this study is to determine whether Dasatinib when added to standard chemotherapy is effective and safe in the treatment of pediatric philadelphia chromosome positive acute lymphoblastic leukemia
Official Title
A Phase 2 Multi-Center, Historically Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Eligibility Criteria
Ages Eligible for Study: 1 Year to 17 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Inclusion Criteria:
- * Newly diagnosed Philadelphia chromosome positive Acute Lymphoblastic Leukemia (ALL)* Age \>1 year and \< less than 18 years old* Induction chemotherapy ≤ 14 days according to institutional standard of care* Adequate liver, renal and cardiac function
Exclusion Criteria:
- * Prior treatment with a Oncogene fusion protein (BCR-ABL) inhibitor* Extramedullary involvement of the testicles* Active systemic bacterial, fungal or viral infection* Down syndrome
Investigator(s)
Neyssa Marina
Contact us to find out if this trial is right for you.
Contact
Pediatric Hematology/Oncology
650-723-5535
View on ClinicalTrials.gov
